ClinVar Miner

Submissions for variant NM_001378454.1(ALMS1):c.7373_7376del (p.Asp2458fs)

dbSNP: rs1370417967
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000672392 SCV000797491 likely pathogenic Alstrom syndrome 2018-01-26 criteria provided, single submitter clinical testing
Invitae RCV000672392 SCV001592097 pathogenic Alstrom syndrome 2023-11-29 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Asp2459Alafs*18) in the ALMS1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ALMS1 are known to be pathogenic (PMID: 17594715). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Alstrom syndrome (PMID: 25846608). ClinVar contains an entry for this variant (Variation ID: 556391). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV002386150 SCV002672093 pathogenic Cardiovascular phenotype 2023-09-07 criteria provided, single submitter clinical testing The c.7376_7379delATAG pathogenic mutation, located in coding exon 8 of the ALMS1 gene, results from a deletion of 4 nucleotides at nucleotide positions 7376 to 7379, causing a translational frameshift with a predicted alternate stop codon (p.D2459Afs*18). In a cohort of individuals with Alstrom syndrome, this mutation was identified in 2 alleles (Marshall JD et al. Hum. Mutat., 2015 Jul;36:660-8). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Natera, Inc. RCV000672392 SCV002082868 pathogenic Alstrom syndrome 2021-09-02 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.